PubMed
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting GH-releasing hormone analog
Teichman et al., 2006
GH SecretagoguesResearch OnlyD
CJC-1295 (no DAC)
Modified GRF 1-29
Short-acting CJC/GRF variant used for pulse-style GH protocols.
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 3
- Research grade
- D
- Experience
- 56
- Activity
- 42
Overall check-ins
Trackers & reports
Overview
About CJC-1295 (no DAC)
Short-acting CJC/GRF variant used for pulse-style GH protocols.
- Category
- GH Secretagogues
- Regulatory status
- Research Only
- Also known as
- Modified GRF 1-29
- Self-reports
- 81
Community
What 81 users report
81 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 2% · Mixed 98% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Sleep
203
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Headache
198
Self-reported dose per injection
Median bucket: 0.2–0.4 mg · Most common: 0.2–0.4 mg
Reports span 0.05–2 mg
0.05–0.1 mg
12
0.1–0.2 mg
64
0.2–0.4 mg
117
0.4–0.6 mg
5
1–2 mg
5
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 88% said they felt similar to their last entry, 13% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 68 days · Based on 32 repeat reporters
Research
Cited research (2)
Source
PubMed
Growth hormone-releasing peptides: clinical applications
Ghigo et al., 2008
Tools
Explore more
Explore
More ways to learn about CJC-1295 (no DAC) from observational PeptIQ data.
Compare with
Related peptides
Help
Frequently asked
What do PeptIQ users report about CJC-1295 (no DAC)?
This page summarizes 81 anonymized self-reports from PeptIQ users who track CJC-1295 (no DAC), including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
How do side effects relate to overall experience for CJC-1295 (no DAC)?
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
What research is cited for CJC-1295 (no DAC)?
2 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is CJC-1295 (no DAC) safe to use?
This wiki does not assess safety or recommend use. CJC-1295 (no DAC) is listed as Research Only. Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of CJC-1295 (no DAC)?
Research, primarily in animal models, suggests CJC-1295 (no DAC) may have a wide range of therapeutic potentials due to its ability to promote angiogenesis (formation of new blood vessels), stimulate collagen synthesis, and modulate inflammatory responses.
SourceWhat is the legal status of CJC-1295 (no DAC)?
CJC-1295 (no DAC) is not approved by the FDA for any human use. There is no legal basis for selling it as a drug, food, or dietary supplement in the United States. The FDA has classified CJC-1295 (no DAC) as a Category 2 bulk drug substance, which explicitly prohibits licensed compounding pharmacies from using it in compounded medications.
SourceWhat are the known or theoretical side effects and risks of CJC-1295 (no DAC)?
The safety and effectiveness of CJC-1295 (no DAC) have not been thoroughly evaluated in humans through rigorous clinical trials. This lack of human data means that safe dosages, short-term side effects, and long-term health consequences are largely unknown.
SourceWhat is the current state of research on CJC-1295 (no DAC)?
While there are over 200 published studies on CJC-1295 (no DAC), the vast majority are animal or in vitro (cell) studies. These preclinical studies consistently show positive results across various tissue types. However, there is a significant lack of comprehensive human clinical trial data.
Source